Globex Laboratories (R&D) Limited - Due diligence report

A 360° intelligence report on Globex Laboratories (R&D) Limited: trust score, financial health, credit view, compliance, directors, growth a…

1998-06-29 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
View plans Plan
GL Globex Laboratories (R&D) Limited
View plans Plan
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Globex Laboratories (R&D) Limited — 360° Intelligence Report

Generated from MCA filings & public records
95/100
Trust Score
Low Risk

Globex Laboratories (R&D) Limited is assessed as Low Risk with a Trust Score of 95/100. Globex Laboratories (R&D) Limited is an active public limited indian non-government company incorporated in 1998, operating in the Chemicals and Materials sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 09 Jul 2026 from the latest processed filings. Globex Laboratories (R&D) Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
95/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (BBB-).

Charges position: 1 open (8.00 cr) · 5 satisfied (31.90 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others4 48.0 cr
Tata Capital Financial Services Limited1 48.0 cr
Icici Bank Limited1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SHAKUN HARISH GOSWAMY 01234567 Director 01/04/2018 6 yrs Approved
NEERAV HARISH GOSWAMY 01234567 Director 01/04/2018 6 yrs Approved
HARISH CHUNILAL GOSWAMY 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: SHAKUN HARISH GOSWAMY (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 28+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence95/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment95/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 8.00 cr already registered.
  • Compliance record supports lending.
Investor view95/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
12 Mar 2024
Charge satisfied
Others
18 Feb 2021
Charge satisfied
Others
24 Dec 2020
Charge created
Others - 50.00 Lakh
23 Dec 2020
Charge created
Others - 8.00 cr
23 Jun 2020
Director ceased
SAURABH HARISH GOSWAMY
30 Apr 2019
Charge satisfied
Tata Capital Financial Services Limited
31 Mar 2016
Share transfer (FY 2016)
599100.00000000 shares to HARISH SAURABH
06 Oct 2015
Charge created
Others - 9.00 cr
31 Mar 2015
Securities allotted
1000000.00 Equity Shares - 1.44 cr raised
31 Mar 2014
Securities allotted
999400.00 Equity Shares - 99.94 Lakh raised
18 Apr 2013
Charge created
Tata Capital Financial Services Limited - 13.00 cr
28 Mar 2013
Securities allotted
500000.00 Preference Shares - 50.00 Lakh raised
Securities allotted
699700.00 Equity Shares - 69.97 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BBB- from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Indusbiotech U24231MH1995PLC085656 Pune, Maharashtra, India
Sterimed Group U74899DL1991PTC046699 Delhi, Delhi, India
Tex Year Industrial Adhesives Private Limited U25199MH2008PTC186360 Mumbai, Maharashtra, India
Ravindra And Company Limited U15511KA1975PLC002773 Bidar, Karnataka, India
Om Pharmaceuticals Limited U24230MH1994PLC082689 Mumbai, Maharashtra, India
Pan Drugs U24230GJ1993PLC020671 Vadodara, Gujarat, India
Titan Paints Private Limited U24222TZ1945PTC000222 Coimbatore, Tamil Nadu, India
Terratech Intermediates (India) Private Limited U24231GJ1994PTC022481 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Globex Laboratories (R&D) Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Globex Laboratories (R&D) Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Globex Laboratories (R&D) Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 95/100, distress signals and MSME payment-delay disclosures - know whether Globex Laboratories (R&D) Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Globex Laboratories (R&D) Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Globex Laboratories (R&D) Limited an active company?

Globex Laboratories (R&D) Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Globex Laboratories (R&D) Limited financially healthy?

Globex Laboratories (R&D) Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Globex Laboratories (R&D) Limited?

Its overall Trust Score is 95/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Globex Laboratories (R&D) Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Globex Laboratories (R&D) Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 5 earlier charge(s) stand satisfied.

Is Globex Laboratories (R&D) Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Globex Laboratories (R&D) Limited?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.